RCS - Haydale Graphene Ind - Finalist for Collaborate to Innovate Awards

Haydale Graphene IndustriesAnnouncement

01/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221201:nRSA1682Ia&default-theme=true

RNS Number : 1682I  Haydale Graphene Industries PLC  01 December 2022

 
 REACH
 For immediate release  01 December 2022

Haydale Graphene Industries plc

 

('Haydale' or the 'Group')

 

Haydale Finalist for The Engineer's Collaborate to Innovate Awards for
MicroRNA Sensor

 

Haydale (AIM: HAYD), the global technology solutions company, is delighted to
announce that it has been shortlisted for The Engineer's Collaborate to
Innovate Awards (C2I) for its work with the Wales Kidney Research Unit
("WKRU") at Cardiff University on a microRNA sensor for kidney transplant
patients.

 

The collaborative team including Haydale, WKRU, Cardiff University Systems
Immunity Research Institute, Cardiff University School of Medicine, Cardiff
University School of Chemistry, Cardiff and Vale University Health Board and
University Hospital of Wales are one of six finalists in the Healthcare and
Medical Category for The Engineer's seventh annual C2I Awards.

 

Already a winner of the Kidney Research UK MedTech Competition, the urinary
electrochemical microRNA sensor has the potential to replace slower and more
costly PCR-based methods for the rapid detection of problems with newly
transplanted kidneys. The sensor uses Haydale's biomedical functionalised
graphene ink to accelerate detection without the need for an invasive biopsy.

 

This nomination will support the commercial progress that Haydale is making
with its biosensor inks, which have been focused on diabetes monitoring and
management. It is anticipated that this will be expanded to wider diagnostics
as the technology is adopted.

 

Keith Broadbent, Haydale's CEO, said he was delighted the team's hard work had
been recognised, commenting:

 

"This is further recognition of our work in healthcare. Our collaboration has
helped to accelerate the provision of cutting-edge technological solutions to
improve people's life experience. Using functionalised graphene reduces sensor
production time and variability and accelerates translation to improve patient
outcomes."

 

Dr Tim Bowen, Reader in Matrix and Molecular Biology at Wales Kidney Research
Unit, added:

 

"The team are delighted to be finalists for the C2I awards. Transplants are
life-changing, but when they fail the consequences can be devastating. This
urinary electrochemical microRNA sensor technology could help identify
problems earlier, leading to more timely clinical interventions."

 

The very best in UK collaborations and innovations in engineering will come
together in London on Thursday 23 February 2023 for the C2I winners' party.

- Ends -

For further information:

Haydale Graphene Industries plc

Keith Broadbent,
CEO
                Tel: +44 (0) 1269 842946

Sarah Thomas, Marketing Manager
                                            Tel: +44
(0) 1269 507026

 

finnCap (Nominated Adviser & Broker)

Julian Blunt / Edward Whiley, Corporate Finance
                                 Tel: +44 (0) 20 7220 0500

Andrew Burdis, ECM

 

Notes to Editors

 

Haydale is a global technologies and materials group that facilitates the
integration of graphene and other nanomaterials into the next generation of
commercial technologies and industrial materials. With expertise in graphene,
silicon carbide and other nanomaterials, Haydale can deliver improvements in
electrical, thermal, and mechanical properties, as well as toughness through
its state-of-the-art functionalisation. Haydale has granted patents for its
technologies in Europe, USA, Australia, Japan, and China and operates from
five sites in the UK, USA, and the Far East.

 

For more information please visit: www.haydale.com (http://www.haydale.com)
 

 

LinkedIn: Haydale-ltd

Twitter: @haydalegraphene

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed
at assisting listed and unlisted (including AIM quoted) companies to
distribute non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not a Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFDDFASEESEIF